398 related articles for article (PubMed ID: 29912605)
21. Tolerance in Solid-Organ Transplant.
Fine RN
Exp Clin Transplant; 2016 Nov; 14(Suppl 3):1-5. PubMed ID: 27805501
[TBL] [Abstract][Full Text] [Related]
22. New paradigms in immunosuppression.
Huizinga R; Voyer T
CANNT J; 2003; 13(3):66-8. PubMed ID: 14596200
[TBL] [Abstract][Full Text] [Related]
23. Pediatric transplantation and tolerance: past, present, and future.
Kamran Hejazi Kenari S; Mirzakhani H; Saidi RF
Pediatr Transplant; 2014 Aug; 18(5):435-45. PubMed ID: 24931282
[TBL] [Abstract][Full Text] [Related]
24. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.
Pascual J; Royuela A; Fernández AM; Herrero I; Delgado JF; Solé A; Guirado L; Serrano T; de la Torre-Cisneros J; Moreno A; Cordero E; Gallego R; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2016 Dec; 18(6):819-831. PubMed ID: 27600985
[TBL] [Abstract][Full Text] [Related]
25. Malignancy After Lung Transplantation: How to Manage Immunosuppression?
Wang X; Dong M
Transplant Proc; 2020; 52(1):315-320. PubMed ID: 31948800
[TBL] [Abstract][Full Text] [Related]
26. Refining the definition and management of high-risk organ transplant recipients.
Hricik DE
Curr Opin Organ Transplant; 2009 Dec; 14(6):634-5. PubMed ID: 19920762
[No Abstract] [Full Text] [Related]
27. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Mansour M; Hill L; Kerr J
Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
[TBL] [Abstract][Full Text] [Related]
28. Top 10 Things Primary Care Physicians Should Know About Maintenance Immunosuppression for Transplant Recipients.
Lien YH
Am J Med; 2016 Jun; 129(6):568-72. PubMed ID: 26714210
[TBL] [Abstract][Full Text] [Related]
29. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
OʼLeary JG; Samaniego M; Barrio MC; Potena L; Zeevi A; Djamali A; Cozzi E
Transplantation; 2016 Jan; 100(1):39-53. PubMed ID: 26680372
[TBL] [Abstract][Full Text] [Related]
30. [Perspectives of immunosuppressive therapy].
Meuer S; Sido B; Dengler T
Chirurg; 1996 Apr; 67(4):310-7. PubMed ID: 8646915
[TBL] [Abstract][Full Text] [Related]
31. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
32. Tacrolimus in transplant rejection.
Rath T
Expert Opin Pharmacother; 2013 Jan; 14(1):115-22. PubMed ID: 23228138
[TBL] [Abstract][Full Text] [Related]
33. Solid Organ Transplantation and Survival among Individuals with a History of Cancer.
Engels EA; Haber G; Hart A; Lynch CF; Li J; Pawlish KS; Qiao B; Yu KJ; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1312-1319. PubMed ID: 33926864
[TBL] [Abstract][Full Text] [Related]
34. Generic immunosuppression in solid organ transplantation: a Canadian perspective.
Harrison JJ; Schiff JR; Coursol CJ; Daley CJ; Dipchand AI; Heywood NM; Keough-Ryan TM; Keown PA; Levy GA; Lien DC; Wichart JR; Cantarovich M
Transplantation; 2012 Apr; 93(7):657-65. PubMed ID: 22267158
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppression in pediatric liver transplant recipients: Unique aspects.
Miloh T; Barton A; Wheeler J; Pham Y; Hewitt W; Keegan T; Sanchez C; Bulut P; Goss J
Liver Transpl; 2017 Feb; 23(2):244-256. PubMed ID: 27874250
[TBL] [Abstract][Full Text] [Related]
36. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological manipulation of the rejection response.
Hopkins PM
Methods Mol Biol; 2006; 333():375-400. PubMed ID: 16790860
[TBL] [Abstract][Full Text] [Related]
38. Induction therapy: why, when, and which agent?
Krischock L; Marks SD
Pediatr Transplant; 2010 May; 14(3):298-313. PubMed ID: 20345609
[TBL] [Abstract][Full Text] [Related]
39. Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant.
Bhowmick M; Auckbarallee F; Edgar P; Ray A; Dasgupta S
Exp Clin Transplant; 2016 Feb; 14(1):17-21. PubMed ID: 26862819
[TBL] [Abstract][Full Text] [Related]
40. Deep cutaneous fungal infections in solid-organ transplant recipients.
Galezowski A; Delyon J; Le Cleach L; Guégan S; Ducroux E; Alanio A; Lastennet D; Moguelet P; Dadban A; Leccia MT; Le Pelletier F; Francès C; Lebbé C; Barete S;
J Am Acad Dermatol; 2020 Aug; 83(2):455-462. PubMed ID: 31931081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
